Alison Milhous
Fortune : 5 791 $ au 31/08/2026
Fortune : 5 791 $ au 31/08/2026
Alison Tjosvold Milhous is currently an Independent Director at VivoSim Labs, Inc. since 2020 and Vice President-Accounting at Erasca, Inc. since 2021.
Formerly, Ms. Milhous was an Audit Partner at Grant Thornton LLP from 2015 to 2019.
Education includes undergraduate studies at California Polytechnic State University (San Luis Obispo).
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
VIVOSIM LABS INC 0,77 % | 13/08/2026 | 19 899 ( 0,77 % ) | 5 791 $ | 31/08/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| VIVOSIM LABS, INC. | Directeur/Membre du Conseil | 15/09/2020 |
| ERASCA, INC. | Comptroller/Controller/Auditor | 01/11/2021 |
| Sociétés | Poste | Fin |
|---|---|---|
Grant Thornton LLP
Grant Thornton LLP Miscellaneous Commercial ServicesCommercial Services Provides accounting, assurance, tax and advisory services | Corporate Officer/Principal | 01/09/2019 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 4 |
|---|---|
VivoSim Labs, Inc.
VivoSim Labs, Inc. BiotechnologyHealth Technology Engages in developing and commercializing functional human tissues | Health Technology |
Grant Thornton LLP
Grant Thornton LLP Miscellaneous Commercial ServicesCommercial Services Provides accounting, assurance, tax and advisory services | Commercial Services |
California Polytechnic State University (San Luis Obispo)
California Polytechnic State University (San Luis Obispo) Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Erasca, Inc.
Erasca, Inc. Pharmaceuticals: MajorHealth Technology Develops, discovers and commercializes therapies for RAS/MAPK pathway-driven cancers | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national